COMP <GO>
CLDI vs PMCB // REVENUE GROWTH (YOY)
Calidi Biotherapeutics Inc. (NYSE) VS. PharmaCyte Biotech Inc. (NASDAQ) • 15-METRIC TALLY: CLDI 1
— PMCB 2
■ METRIC PARITY
LAST: $0.67 (-4.29%) • MKT CAP: $2.5M
revenue-growth
—
LAST: $0.33 (-0.78%) • MKT CAP: $3.6M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLDI VS. PMCB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLDI | PMCB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -30.20% | -4.80 | PMCB | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 28.2 | 25.9 | +2.33 | CLDI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.5M | $3.6M | -$1.1M | PMCB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLDI REV | PMCB REV | CLDI GROSS % | PMCB GROSS % | CLDI FCF | PMCB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$21.3M | -$5.2M |
| FY 2024 | $0 | $0 | — | — | -$19.7M | -$3.0M |
| FY 2023 | $0 | $0 | — | — | -$27.0M | -$2.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLDI // BETA —
PMCB // BETA —